20-F: NovaBridge Biosciences Amends Collaboration Agreement

NovaBridge Biosciences and I-MAB Biopharma US Limited have entered into Amendment Eight to their Collaboration Agreement, effective November 2, 2025, modifying terms related to development cost sharing and regulatory control.

Summary

• NovaBridge Biosciences (formerly I-Mab) and I-Mab US have executed Amendment Eight to their Collaboration Agreement, effective November 2, 2025.
• The amendment modifies Section 3.4.4(c) regarding cost sharing and invoicing, effective January 1, 2025.
• It clarifies that shared development costs will include clinical trials conducted inside and outside the Rest of World, including in Greater China, to support global development and regulatory applications for CLDN18.2/4-1BB BsAb and PD-L1/4-1BB BsAb.
• The amendment also details regulatory responsibilities, granting the Lead Party sole rights for regulatory submissions and approvals in the Rest of the World.
• I-Mab US is the Lead Party for CLDN18.2/4-1BB BsAb, and ABL Bio is the Lead Party for PD-L1/4-1BB BsAb.
• Section 6.5 concerning Joint Committee decisions has been revised to include a CEO resolution process for unresolved matters.
• Ownership of BsAb Improvements in the Rest of the World will be jointly owned (50/50), with costs for patent prosecution borne by the Lead Party.
• A new Section 4.3.5 has been added, stating that profits from commercialization of a Product in the Rest of the World, where both parties agree to participate in development and commercialization, shall be shared equally.
• The amendment supersedes prior agreements in case of conflict and is incorporated by reference into the Existing Agreement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the amendments provide greater clarity and structure to the collaboration, which is crucial for advancing complex drug development programs.

Positives

• Clarifies cost-sharing and invoicing procedures for development costs, potentially improving financial predictability.
• Defines clear regulatory responsibilities, streamlining the path to market for the CLDN18.2/4-1BB BsAb and PD-L1/4-1BB BsAb.
• Establishes a mechanism for resolving Joint Committee deadlocks through CEO intervention, potentially speeding up decision-making.
• Introduces equal profit sharing for jointly developed products in the Rest of the World, aligning financial incentives.
• The amendment aims to provide greater clarity and efficiency in the ongoing collaboration between NovaBridge Biosciences and I-Mab US.

Negatives

• The amendments are effective retrospectively from January 1, 2025, which may require adjustments to prior accounting.
• The complexity of the amendments could lead to potential interpretation issues or disputes if not clearly implemented.

Risks

• Potential for disputes regarding the interpretation or implementation of the revised cost-sharing and profit-sharing clauses.
• The effectiveness of the CEO resolution process for Joint Committee deadlocks is dependent on the willingness and ability of CEOs to reach a resolution.
• Changes in regulatory control allocation could lead to disagreements if one party feels its interests are not adequately represented.

Future Outlook

The amendments aim to streamline development and commercialization processes for the CLDN18.2/4-1BB BsAb and PD-L1/4-1BB BsAb, potentially leading to more efficient progress and clearer financial outcomes.

Industry Context

StockSavvy.ai notes that amendments to collaboration agreements are common in the biopharmaceutical industry as companies refine development strategies and navigate complex regulatory landscapes. This amendment reflects a continued effort by NovaBridge Biosciences and I-Mab US to optimize their partnership for the development of novel bispecific antibodies.

Stakeholder Impact

• Shareholders may benefit from potentially more efficient development and commercialization of the partnered drug candidates.
• The clarity on cost sharing and profit distribution could lead to more predictable financial outcomes for the collaboration.

Next Steps

• Parties to implement the revised cost-sharing and invoicing procedures effective January 1, 2025.
• Parties to adhere to the new regulatory control and submission responsibilities.
• Monitor the effectiveness of the CEO resolution process for Joint Committee matters.
• Continue development and commercialization efforts for CLDN18.2/4-1BB BsAb and PD-L1/4-1BB BsAb in accordance with the amended agreement.

Key Dates

Keywords

Collaboration Agreement Amendment, ABL Bio, I-MAB Biopharma US Limited, CLDN18.2/4-1BB BsAb, PD-L1/4-1BB BsAb, Development Cost Sharing, Regulatory Approvals, Joint Committee, Intellectual Property, Biotechnology, Pharmaceuticals